







































Clinical Effectiveness and Safety of Treatment With
Anti–TumorNecrosis Factor αDrugs in a Cohort of Colombian
Patients With Rheumatoid Arthritis
Pedro Santos-Moreno, MD, MSc* and Guillermo Sánchez-Vanegas, PhD†
Objective: To compare the clinical response at 24 months and evaluate
the adverse events (AEs) of patients with rheumatoid arthritis (RA) treated
with etanercept 50 (injectable solution 50 mg prefilled syringe), etanercept
25 (lyophilized 25 mg), infliximab, adalimumab, or golimumab.
Methods: A cohort study was carried out in patients with RA, in treat-
ment with etanercept (injectable solution 50 mg prefilled syringe or lyoph-
ilized 25 mg), infliximab, adalimumab, or golimumab. Duration of study:
follow-up was carried out for 24 months. The difference of initial and final
28-joint Disease Activity Score, remission incidence, difference of initial
and final Health Assessment Questionnaire score, disability recovery, and
AE rate were evaluated.
Results: The study enrolled 435 patients (108 adalimumab, 107 infliximab,
92 etanercept 25mg, 81 etanercept 50mg, and 47 golimumab). For etanercept
50, the median difference between basal and at the end of follow-up 28-joint
Disease Activity Score was 1.7. For golimumab, it was 1.4; for adalimumab,
it was 1.1; for etanercept 25, it was 1.02; and for infliximab, it was 0.96
(p= 0.001). Themedian difference between basal and finalHealthAssessment
Questionnaire ranged was 1.66 for etanercept 50, 1.34 for etanercept 25, 1.3
for golimumab, 1.24 for adalimumab, and 1.07 for infliximab (p = 0.0005).
Comparatively, etanercept 50 presented the highest cumulative incidence
(77%; 95% confidence interval [CI], 67%–86%) and remission incidence
(64 cases per 100 person-months; 95% CI, 4.9–8.1 cases per 100 person-
months) and the lowest AE rate (8.6 per 100 person-years; 95% CI, 5.3–15
per 100 person-years).
Conclusions: In patients with RA treatedwith anti–tumor necrosis factor
α drugs, the highest incidence of remission and the lowest rate of AEswere
documented for the cohort exposed to etanercept 50 mg.
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T umor necrosis factor α (TNF-α), interferons β and γ, andinterleukins 1, 2, and 6 are part of the set of promoters of
the inflammatory process, linked to the physiopathogenesis of
rheumatoid arthritis (RA).1,2 In the early stages of the disease,
TNF-α is significantly expressed in the synovial tissue and lo-
cally stimulates the generation of neovascularization processes,
promoting inflammation and increasing the production of other
cytokines, which in turn favor the migration of white cells
within the joint.2,3 Based on this knowledge, the treatment of
RA has been evolving during the last decades, and part of the
available alternatives is focused on controlling this autoim-
mune phenomenon that causes an excessive inflammatory pro-
cess.4 Within these options, there are antirheumatic drugs of
biological origin modifying the disease (disease-modifying an-
tirheumatic drugs [DMARDs] biologic); some of them look for
a specific effect on TNF-α and are known as anti–TNF-α
drugs. In this group are etanercept adalimumab, golimumab,
and infliximab, among others. All of them have proved to be ef-
fective and relatively safe, which has allowed them to be suc-
cessfully included in the current RA treatment regimens.5,6
A key factor that has been described as a determinant of effec-
tiveness is the adherence to medication, which in turn may be in-
fluenced by its route of administration and its dose frequency. It is
for this reason that some authors have described that anti–TNF-α
subcutaneous application can achieve better adherence rates than
other orally administered drugs or other more complex schemes,
which could translate into higher rates of clinical response.7,8
It is important to note that most of the evidence supporting
the efficacy of anti–TNF-α comes from clinical trials in which,
generally, the molecule of interest has been compared against pla-
cebo.9 Despite the methodological advantages of these designs,
because of their ability to control potential confounding biases,
it is also important to bear in mind that these studies, by being ide-
ally developed,3,10–12 do not necessarily allow for finding out the
effectiveness and performance of these drugs in conditions similar
to those of real life and in direct comparisons with the best avail-
able treatments. Consequently, it is essential to have real-life data,
in which it is possible to verify or contrast the clinical effect of
these therapies, based on head-to-head comparisons.13 Based on
the above, the present cohort study was carried out, with the objec-
tive of comparing the 24-month clinical response and evaluating
the adverse events (AEs) of a cohort of patients with RA treated
with one of the following medications: etanercept 25 (lyophilized
25 mg), etanercept 50 (injectable solution 50 mg prefilled sy-
ringe), infliximab, adalimumab, and golimumab.
MATERIALS AND METHODS
Design, Population, and Sample
An observational cohort analytical study was conducted in a
reference center for patients with RAwho are treated under the con-
cept of Center of Excellence in the city of Bogotá, Colombia. This
institution has a registry of the patients treated, which made it pos-
sible to include the entire census of subjects older than 18 years,
with a confirmed diagnosis of RA according to the criteria of the
American College of Rheumatology/European League Against
Rheumatism,14 with active disease despite being in treatment with
conventional DMARDs, for whom the attending physician consid-
ered starting a treatment scheme with one of the following biologic
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